Synchronous Hodgkin lymphoma and gastric adenocarcinoma

Hodgkin lymphoma (HL) is a lymphoproliferative disease arising in the lymphoid tissue, which is characterized by Reed–Sternberg cells. Adenocarcinoma is the most frequent pathological type of stomach cancer. Improved survival in HL patients leads to the development of secondary malignancies. However, synchronous occurrence of these 2 malignancies is extremely rare. Here, we present a 45-year-old male complaining of a lymph node mass in the neck, without any abdominal symptoms, diagnosed as HL and gastric adenocarcinomawith hepatitis B carrier status. We treated the patient with 8 courses of pirarubicin bleomycin, vincristine, and dacarbazine (modified ABVD), and 4 courses of capecitabine therapy concurrently along with oral entecavir, as the patient survived longer than 20 months. The prognosis of multiple primary malignancies is poor because therapy is difficult, without a standard treatment. The frequency of multiple primary malignancies is increasing in recent years, and second malignancies in patients with cancer should be taken into consideration. Abbreviations: CT = computerized tomography, EBV = Epstein–Barr virus, ECF = epirubucin 50 mg/m, cisplatin 60 mg/m, 5fluorouracil 1000 mg/m and leucovorin 15 mg, FDG = Fluorodeoxyglucose, FUFA = 5-fluorouracil 725 mg days 1–5 and leucovorin 35 mg days 1–5, HBV = hepatitis B virus, HL = Hodgkin lymphoma, LDH = lactic dehydrogenase, MALT = mucosa-associated lymphoid tissue, Modified ABVD = pirarubicin, bleomycin, vincristine, and dacarbazine, NHL = non-Hodgkin lymphoma, SUV = standard uptake value.